Výsledky vyhledávání

Future care for long-term cancer survivors: towards a new model

Publikováno v: Clinical & Translational Oncology
CLINICAL & TRANSLATIONAL ONCOLOGY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
Scientia
Biblos-e Archivo. Repositorio Institucional de la UAM

Purpose: The increase in the prevalence "long-term cancer survivor” (LCS) patients is expected to increase the cost of LCS care. The aim of this study was to obtain information that would allow to optimise the current model of health management in

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84626cacb4be04af30f91cb66c0afb22
https://hdl.handle.net/10486/700759

Zobrazit plný text záznamu

Akademický článek

Bintrafusp Alfa With CCRT Followed by Bintrafusp Alfa Versus Placebo With CCRT Followed by Durvalumab in Patients With Unresectable Stage III NSCLC: A Phase 2 Randomized Study.

Autor: Vokes EE; University of Chicago Medicine and Biological Sciences, Chicago, Illinois., Mornex F; Centre Hospitalier Universitaire, Lyon, France., Sezer A; Baskent University Adana Application and Research Center, Turkey., Cheng Y; Jilin Cancer Hospital, People's Republic of China., Fang J; Beijing Cancer Hospital, People's Republic of China., Baz DV; Hospital Universitario Virgen Macarena, Spain., Cil T; Adana City Hospital, Health and Science University, Adana, Turkey., Adjei AA; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio., Ahn MJ; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Barlesi F; Aix-Marseille University, Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM), Cancer Research Center of Marseille (CRCM), Assistance Publique Hopitaux de Marseille (APHM), Marseille, France; Paris-Saclay University, Gustave Roussy Cancer Campus, Villejuif, France., Felip E; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain., Garon EB; David Geffen School of Medicine at the University of California, Los Angeles (UCLA), Los Angeles, California., Audhuy F; Merck Serono S.A.S. (an affiliate of Merck KGaA, Darmstadt, Germany), Lyon, France., Ito R; Merck Biopharma Co., Ltd., (an affiliate of Merck KGaA, Darmstadt, Germany), Tokyo, Japan., Sato M; Merck Biopharma Co., Ltd., (an affiliate of Merck KGaA, Darmstadt, Germany), Tokyo, Japan., Eggleton SP; Merck Sereno Ltd. Feltham (an affiliate of Merck KGaA, Darmstadt, Germany), Feltham, United Kingdom., Martin CM; Alexander Fleming Institute, Buenos Aires, Argentina., Reck M; Lung Clinic Grosshansdorf, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany., Robinson CG; Washington University in St. Louis School of Medicine, St. Louis, Missouri., Paz-Ares L; Hospital Universitario 12 de Octubre, CNIO-H12o Lung Cancer Unit, Ciberonc, Madrid, Spain; Complutense University, Madrid, Spain. Electronic address: lpazaresr@seom.org.

Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2024 Feb; Vol. 19 (2), pp. 285-296. Date of Electronic Publication: 2023 Oct 04.

Zobrazit plný text záznamu

Akademický článek

Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.

Autor: Le X; Department of Thoracic Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: xle1@mdanderson.org., Paz-Ares LG; Department of Medical Oncology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain., Van Meerbeeck J; Department of Thoracic Oncology, Antwerp University Hospital (UZA), 2650 Edegem, Belgium., Viteri S; Instituto Oncologico Dr. Rosell, Hospital Universitari Dexeus, Grupo QuironSalud, 08028 Barcelona, Spain., Galvez CC; Department of Medical Oncology, Hospital Universitari Sagrat Cor, 08029 Barcelona, Spain., Smit EF; Department of Thoracic Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands., Garassino M; Department of Medicine, Section of Hematology/Oncology, Knapp Center for Biomedical Discovery, The University of Chicago, Chicago, IL 1084250, USA., Veillon R; CHU Bordeaux, Service des Maladies Respiratoires, 33000 Bordeaux, France., Baz DV; Department of Medical Oncology, Hospital Universitario Virgen Macarena, 41009 Seville, Spain., Pradera JF; Department of Medical Oncology, Hospital Universitario Nuestra Señora de Valme, 41014 Seville, Spain., Sereno M; Department of Medical Oncology, Hospital Universitario Infanta Sofia, San Sebastián de los Reyes, 28703 Madrid, Spain., Kozuki T; Department of Respiratory Medicine, NHO Shikoku Cancer Center, Matsuyama City 791-0280, Japan., Kim YC; Department of Internal Medicine, Chonnam National University Medical School and CNU Hwasun Hospital, Hwasun-Gun 58128, Rep. of Korea., Yoo SS; Department of Internal Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu 41566, Rep. of Korea., Han JY; The Center for Lung Cancer, National Cancer Center, Goyang 10408, Rep. of Korea., Kang JH; Division of Medical Oncology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul 06591, Rep. of Korea., Son CH; Department of Internal Medicine, Dong-A University, 840 Hadan 2-dong, Saha-gu, Busan 604-714, Rep. of Korea., Choi YJ; Division of Oncology/Hematology, Department of Internal Medicine, Korea University Anam Hospital, Seoul 02841, Rep. of Korea., Stroh C; Clinical Biomarkers & Companion Diagnostics, the healthcare business of Merck KGaA, 64293 Darmstadt, Germany., Juraeva D; Oncology Bioinformatics, the healthcare business of Merck KGaA, 64293 Darmstadt, Germany., Vioix H; Global Evidence & Value Development, the healthcare business of Merck KGaA, 64293 Darmstadt, Germany., Bruns R; Department of Biostatistics, the healthcare business of Merck KGaA, 64293 Darmstadt, Germany., Otto G; Global Clinical Development, the healthcare business of Merck KGaA, 64293 Darmstadt, Germany., Johne A; Global Clinical Development, the healthcare business of Merck KGaA, 64293 Darmstadt, Germany., Paik PK; Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA; Weill Cornell Medical College, New York 14853, NY, USA.

Publikováno v: Cell reports. Medicine [Cell Rep Med] 2023 Nov 21; Vol. 4 (11), pp. 101280. Date of Electronic Publication: 2023 Nov 08.

Zobrazit plný text záznamu

Akademický článek

Future care for long-term cancer survivors: towards a new model.

Autor: Provencio M; Medical Oncology Department, Spanish Lung Cancer Group (GECP), Hospital Universitario Puerta de Hierro Majadahonda, Calle Manuel de Falla 1Majadahonda, 28222, Madrid, Spain. mariano.provencio@salud.madrid.org., Romero N; Cardiology and Cardiac Surgery Clinical Management Unit, Hospital Virgen del Rocio, Sevilla, Spain., Tabernero J; Medical Oncology Department, Hospital Universitario Vall d'HebronVHIOEuropean Society for Medical Oncology (ESMO), Barcelona, Spain., Vera R; Medical Oncology Department, Complejo Hospitalario de NavarraServicio Navarro de la SaludSpanish Society of Medical Oncology (SEOM), Navarra, Spain., Baz DV; Medical Oncology Department, Hospital Universitario Virgen Macarena, Andalusian Comprehensive Oncology Plan, Sevilla, Spain., Arraiza A; Health Programmes, Health Care, Osakidetza, País Vasco, Spain., Camps C; Medical Oncology Department, Hospital General Universitario de ValenciaUniversidad de Valencia CIBERONCECO Foundation, Valencia, Spain., Felip E; Institut d'Oncologia, Vall d'Hebron University Hospital, Spanish Society of Medical Oncology (SEOM), Barcelona, Spain., Garrido P; Department of Medical Oncology, IRYCIS, Hospital Universitario Ramón y Cajal, Spanish Society of Medical Oncology (SEOM), Madrid, Spain., Gaspar B; Spanish Association of Lung Cancer Patients (AEACaP), Valencia, Spain., Llombart M; Valencia Oncology Institute Foundation, Valencia, Spain., López A; Pharmacy, Navarra Health Service-Osasunbidea, Navarra, Spain., Magallón I; Medical Oncology Department, Hospital Universitario Vall d'Hebron, Spanish Oncology Nursing Society (SEEO), Barcelona, Spain., Ibáñez VM; Professional Organization of the Ministry of Health, Madrid, Spain., Olmos JM; Senate Health Committee, Andalusian School of Public Health, Granada, Spain., Mur C; Clínicas CAT Barcelona, Spanish Society of Health Directors (SEDISA), Barcelona, Spain., Navarro-Ruiz A; Hospital Pharmacy ServiceHospital General Universitario de ElcheSpanish Society of Hospital Pharmacy, Alicante, Spain., Pastor A; Spanish Society of Family and Community Medicine (SEMFyC), Madrid, Spain., Peiró M; Universitat Ramon Llull, ESADE, Barcelona, Spain., Polo J; Centro de Salud Casar de Cáceres, Spanish Society of Primary Care Physicians (SEMERGEN), Cáceres, Spain., Rodríguez-Lescure Á; Medical Oncology Department, Hospital General Universitario de Elche, Spanish Society of Medical Oncology (SEOM), Alicante, Spain.

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2022 Feb; Vol. 24 (2), pp. 350-362. Date of Electronic Publication: 2021 Oct 29.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání